n
 
About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Monday, April 11th, 2016

The QualityStocks
Daily Stock List

graphic
graphic

N-Viro International Corp. (NVIC)

StockOodles and OTC Stock Review reported earlier on N-Viro International Corp. (NVIC), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

N-Viro International Corp. is a leader in the conversion of organic materials generated from industrial, agricultural, and municipal sources. The Company integrates advanced technology with 21st-century design for successful commercial application of its alternative energy product called N-Viro Fuel™. N-Viro combines its proprietary, patented technologies, unique services, and materials handling expertise to provide turnkey solutions in soil enrichment and alternative fuel development.  N-Viro International’s sister company is N-Viro Energy Limited. N-Viro International is headquartered in Toledo, Ohio.

The N-Viro patented technology involves mixing a bioorganic material with alkaline reagents, which prepare the bioorganic for a chemical conversion. The production of N-Viro Fuel™ is from bioorganic waste. It provides coal-fired power plants a renewable energy product. N-Viro Fuel™ is an emission control strategy; liberated ammonia helps in NOx removal.

Furthermore, N-Viro Fuel™ is easily mixed with coal; is a Btu biomass-derived fuel; and equipment retrofits are minimal. Additionally, it uses the selective and pre-tested fly ash as an alkaline additive. It can use waste heat from the power plant to the fuel system.

N-Viro International also has its N-Viro Soil™ -  a lime substitute. It is used as a soil amendment, lime substitute, landfill cover, and land reclamation in the U.S., the UK, Israel, Australia and Canada. N-Viro Soil™ improves texture and water-holding capacity in soil to promote root growth.

In October 2015, N-Viro International announced that N-Viro Energy (Hong Kong) Ltd. entered into a three party Memorandum of Understanding (MOU) for Business Cooperation with the Yangtze Delta Region Institute of Tsinghua University, Zhejiang and the Administrative Committee of Jiaxing Science City of the Nanhu District in Jiaxing, China. The agreement outlines a strategy for the three parties to promote technological innovation using the N-Viro collection of technologies to establish a feasible and environmentally sustainable waste-to-electrical energy generation solution.

The three parties agreed to establish the N-Viro China headquarters within Jiaxing Science City. This headquarters will utilize the talents and technical support services of Tsinghua University to create a research organization to explore and incubate the expansion of the N-Viro waste conversion process to include other organic waste feed stocks and expand its energy generating capabilities.

N-Viro International has started on an ambitious project within the Zhejiang Province of China with the Jiaxing City Joint Sewage Treatment Co., Ltd.  Jiaxing City is just outside of Shanghai. The aim of this project is to treat the Jiaxing City biosolids employing the N-Viro Fuel™ process, and subsequently use this product to generate electrical power for the city's residents. Sister company N-Viro Energy Limited has been involved with the provincial governments to attain government approvals for N-Viro International’s project.

N-Viro International Corp. (NVIC), closed Monday's trading session at $1.44, up 1.41%, on 32,831 volume with 47 trades. The average volume for the last 60 days is 22,832 and the stock's 52-week low/high is $0.5811/$2.47.

Intellect Neurosciences, Inc. (ILNS)

Hot Stock Profits, Value Penny Stocks, OtcWizard, and Penny PayDay reported earlier on Intellect Neurosciences, Inc. (ILNS), and we also highlight the Company, here at the QualityStocks Daily Newsletter.

Intellect Neurosciences, Inc. is a research-based biotechnology company. It concentrates on the discovery, development, and licensing of novel disease-modifying therapeutics for the treatment and prevention of rare neurodegenerative orphan diseases with no approved therapies. In 2012, Intellect acquired from Northwestern University exclusive worldwide development and commercialization rights to the monoclonal antibody, TauC3, for the prophylaxis, mitigation and/or treatment of Alzheimer's disease and other tauopathies as described in Intellect’s patent. Intellect Neurosciences has its corporate headquarters in Englewood Cliffs, New Jersey.

Intellect Neurosciences is directing its research efforts exclusively to rare diseases. The Company has adjusted the focus of its TauC3 research and is pivoting from AD to rare neurological diseases that qualify for orphan drug status. Intellect is planning to test its TauC3 monoclonal antibody in a number of orphan disease preclinical models in the near future. The Company will focus its future research efforts exclusively on discovering and advancing therapeutic agents for the treatment and prevention of rare neurological diseases.

Intellect’s compounds under development include OX1. This is a high affinity, copper binding molecule that protects the body against free radicals. OX1 (renamed SHP622) is licensed to Shire plc.

Shire recently completed a single ascending dose and multiple ascending dose Phase 1b clinical study in 55 patients with Friedreich's Ataxia. The design of the study was to evaluate the safety, tolerability, as well as PK/PD of SHP622.

The study is entitled, "A Phase 1, Randomized, Double-blind, Placebo-controlled, Multicenter, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral VP 20629 in Adult Subjects with Friedreich's Ataxia."

Last month, Intellect Neurosciences announced that it appointed Mr. Benjamin D. Freilich, MD, FACS as Senior Medical Affairs Advisor. Dr. Freilich has agreed to assist Intellect Neurosciences in shaping and guiding the Company's CONJUMAB-A antibody drug conjugate (ADC) program, and specifically, to advise it on the design of CONJUMAB-A and future pre-clinical and clinical studies targeting Age-Related Macular Degeneration (AMD).

Intellect Neurosciences, Inc. (ILNS), closed Monday's trading session at $0.0705, down 10.76%, on 21,007 volume with 5 trades. The average volume for the last 60 days is 22,421 and the stock's 52-week low/high is $0.05/$0.40.

5BARz International, Inc. (BARZ)

AllPennyStocks reported last week on 5BARz International, Inc. (BARZ), OTC Markets Group did previously, and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

San Diego, California-based 5BARz International, Inc. is a technology leader in the cellular network extender industry. The Company focuses on the worldwide commercialization of a patented product technology branded under the name 5BARz™.  5BARz™ is a cellular network infrastructure device for use in the small office, home, or for when users are mobile. 5BARz™ represents an important solution for cellular network operators in providing clear, high quality signal for their subscribers with a growing need for high quality connectivity.  5BARz International lists on the OTC Markets Group’s OTCQB.

5BARz International’s products include the 5BARz Network Extender and the 5BARz Road Warrior. 5BARz™ incorporates a patented technology to create a highly engineered, single-piece, plug 'n play unit. It strengthens weak cellular signals to deliver high quality signals for voice, data, and video reception on cell phones and other cellular equipped devices.

The Company’s unique product is the 5BARz Network Extender™. The 5Barz Network Extender™ is a “carrier grade” cellular network infrastructure device. It can be remotely managed from each carrier’s Network Operation Center. The 5Barz Network Extender™ includes patented technologies, including bringing together the send and receive antenna into a single form factor, automatically cancels echo or “noise cancellation”, supports multiple bands and all frequencies globally, and automatically balances power management to avoid any interference with the macro network. It can support up to ten simultaneous users at a time.

5BARz established a subsidiary Company, 5BARz India Private Ltd., in Bangalore, India. 5BARz India is a wholly-owned subsidiary of 5BARz. It is licensed the exclusive rights to market and distribute all of 5BARz products across India in perpetuity. 5BARz India has started commercial rollout of the 5BARz™ Network Extender in India.

Recently, 5BARz International announced that it topped off a private placement completed by the Company with the recent equity investment of $1,110,000.

Mr. Daniel Bland, 5BARz International’s Chief Executive Officer, stated: “Following the recent series of orders received by the Company from Tier 1 cellular network operators in India, these funds provide a critical element for the expansion of our business and production capability in a market with 981 million cellular phone subscribers. Our management team in India are focused upon achieving rapid penetration into this marketplace. To date the cellular network operators for which our products have been tested and approved, and with whom we have established a position as 'approved vendor', represent 42 percent of that marketplace.”

5BARz International, Inc. (BARZ), closed Monday's trading session at $0.078, up 8.33%, on 146,100 volume with 16 trades. The average volume for the last 60 days is 269,085 and the stock's 52-week low/high is $0.0451/$0.20.

Manhattan Scientifics, Inc. (MHTX)

Hawk Associates and SmallCapVoice reported on Manhattan Scientifics, Inc. (MHTX), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Manhattan Scientifics, Inc. centers on the commercialization of disruptive technologies in the nano-medicine space. At present, it is developing commercial medical prosthetics applications for its ultra-fine grain metals. The Company’s goal is to commercialize the cancer research work and nano medical applications developed by Senior Scientific LLC, its wholly-owned subsidiary. Manhattan Scientifics has offices in New Mexico, New York, and Montreal, Quebec.

Manhattan Scientifics has expertise in licensing from the national laboratories (the Los Alamos National Laboratory (LANL) and the Sandia National Laboratory (SNL)) and in working with individual inventors. The Company’s technology uses iron oxide nanoparticles and a technique it calls Magnetic Relaxometry to locate and measure cancers with a sensitivity that would provide a diagnosis years before other known methods.

Manhattan Scientifics acquired the exclusive commercial rights (manufacturing and marketing) to Mr. Edward R. Flynn's (President and Chief Executive Officer of Senior Scientific, LLC) patents and Intellectual Property (IP) in the developing field of nano medicine. In particular, Dr. Flynn's work in biomagnetic detection of cancer and other diseases through magnetic field sensors.

The Company creates IP portfolios and business cases supporting new technologies. It guides them to relationships with industrial partners who are well-prepared to launch product. As a result, the lab and inventor see the technology enter the market. The industrial partner gets a strong basis for a new product. Manhattan Scientifics profits from building the licensing bridge to industry.
 
Manhattan Scientifics is now concentrating on nanostructured metals technology via wholly-owned subsidiary Metallicum, Inc.  In addition, it is focusing on nanoparticle based cancer detection by way of Senior Scientific.  Furthermore, it is working on the commencement of product trials on its cancer detection product. The nanostructured metals technology has been revenue producing for some years. The cancer detection technology can detect cancer years earlier.

Manhattan Scientifics has an agreement to collaborate with The University of Texas M.D. Anderson Cancer Center (MDACC) to advance, demonstrate, as well as validate a ground-breaking technology developed by Mr. Edward R. Flynn, PhD, for the very early detection of cancer. Manhattan Scientifics has delivered its innovative cancer measurement instrument to MDACC.

This past February, Manhattan Scientifics announced that Senior Scientific established a research collaboration with Weill Cornell Medicine. For this alliance, the Company will bring its magnetic relaxometry technology to Weill Cornell Medicine. Scientists will investigate the use of molecularly targeted nanoparticles to non-invasively detect and diagnose prostate cancers.

Manhattan Scientifics, Inc. (MHTX), closed Monday's trading session at $0.0591, down 1.34%, on 108,050 volume with 15 trades. The average volume for the last 60 days is 103,227 and the stock's 52-week low/high is $0.0401/$0.11.

Skinvisible, Inc. (SKVI)

Stock Guru, PennyStocks24, Xtremepicks, OurHotStockPicks, and Penny Stock Whispers reported earlier on Skinvisible, Inc. (SKVI), and we report on the Company today, here at the QualityStocks Daily Newsletter.

Skinvisible, Inc., through its wholly-owned subsidiary Skinvisible Pharmaceuticals, Inc., is a pharmaceutical research and development (R&D) company. It has developed and patented a unique polymer delivery system, Invisicare®. In addition, the Company has formulated greater than 40 topical skin products that it out-licenses internationally. Skinvisible is based in Las Vegas, Nevada.

The Company has many patents issued- technology and product patents. Skinvisible’s business model continues to be to out-license its patented prescription and Over-the-Counter (OTC) products featuring Invisicare to established manufacturers and marketers of brands around the world. Moreover, its business model continues to focus on maximizing profits from the products it has already out-licensed.

Skinvisible has created a commercial subsidiary, Kintari USA, Inc. This is to take its cosmeceutical and select OTC products with Invisicare® to market. Kintari USA is a wholly-owned subsidiary of Kintari International, Inc., a wholly-owned subsidiary of Skinvisible. Kinatri USA is marketing a premium line of scientifically formulated skincare products powered by Skinvisible’s patented Invisicare® technology.

Skinvisible says that the demand for its products is enhanced because of the granting of key U.S. and global patents, and also the completed development of several inventive products. The Company has licensees around the world and two of the licensees are now in the marketplace. These are Avon Products worldwide and Women's Choice Pharmaceuticals in the U.S.

Skinvisible Pharmaceuticals announced in September 2015 that it expanded its patent portfolio with a new patent granted by the United States Patent and Trademark Office (USPTO) entitled, "Acne Treatment Composition and Methods for Using." Skinvisible continues to build its worldwide patent portfolio while seeking licensees for its prescription line of dermatology focused products. The demand for a patent protected channel of dermatology products is increasing fast as the global medical dermatology market continues to develop and new molecules are not available. Companies are looking for products that are cost-effective and have patent protection to maximize exclusivity.

Last week, Skinvisible, via Kintari USA, announced the official expansion of its product line to include Kintari's long-lasting Hand & Body Lotion. Kintari's product line now comprises four skincare products. These are all innovatively formulated utilizing Skinvisible’s patented Invisicare® skin delivery technology and developed by scientists from Skinvisible Pharmaceuticals.

Skinvisible, Inc. (SKVI), closed Monday's trading session at $0.02, even for the day, on 61,962 volume with 4 trades. The average volume for the last 60 days is 122,178 and the stock's 52-week low/high is $0.0136/$0.052.

graphic

The QualityStocks
Company Corner

graphic
graphic

Lingo Media Corp. (LMDCF)

The QualityStocks Daily Newsletter would like to spotlight Lingo Media Corp. (LMDCF). Today, Lingo Media Corp. closed trading at $0.781, up 14.37%, on 5,000 volume with 1 trade. The stock’s average daily volume over the past 60 days is 3,690, and its 52-week low/high is $0.10/$0.703.

Lingo Media Corp. subsidiary, ELL Technologies and Gale, a leading provider of library resources and part of Cengage Learning, are pleased to announce that they have entered into a commercial distribution partnership. Through the agreement, Gale will have exclusive international rights to market, sell and distribute ELL Technologies' Scholar English language training program to university and college libraries, public libraries, and private schools. The product will be co-branded as "Gale Lingo" and will be available in the second quarter of 2016.

Lingo Media Corp. (LMDCF) (LM.V) is an EdTech company that's changing the way the world learns English through an innovative combination of proven educational techniques and accessible technology. The company provides both online and print-based solutions through its two distinct business units: ELL Technologies and Lingo Learning. Through ELL Technologies, Lingo has made considerable progress in English-learning markets throughout Latin America. Through print-based publisher Lingo Learning, the company has built a significant presence in the Chinese education market, which includes more than 300 million students.

The company's groundbreaking English programs are developed and marketed for students at every stage of development – from the classroom to the boardroom. This versatility has allowed Lingo to secure contracts and build relationships with clients in a variety of markets around the globe. In Mexico, a subsidiary of the company has partnered with a recognized university that allows it to offer its courses along with certification. In Peru, the company's subsidiary provides its groundbreaking Scholar program to a branch of the country's armed forces.

Through ELL Technologies, Lingo also markets electronic learning solutions that are suitable for pre-readers. Lingo's Kids program – which features cross-platform, multi-browser compatibility – requires no prior knowledge of the English language, allowing the company to address the entire student life cycle in blended learning environments, traditional classroom settings and the home with one cutting-edge solution. The Kids program addresses the critically underserved pre-school market, which includes roughly 181.4 million children across Asia and 30.1 million throughout Latin America and the Caribbean, according to UNESCO.

Although Lingo has traditionally leaned on its print-based offerings as a primary source of revenue, the company's recent efforts to shift into the thriving eLearning market have highlighted the immense potential of a more heavily digital approach. In the second quarter of 2015, Lingo recorded more revenue from digital products than print-based solutions for the first time in its history. With the global eLearning market set to reach $107 billion in 2015, according to a report by Global Industry Analysts, the company's performance and growing foothold in some of the world's most rapidly expanding markets place it in a favorable position. Disclaimer

Lingo Media Corp. Company Blog

Lingo Media Corp. News:

Gale, a Part of Cengage Learning, and Lingo Media Enter Into Global Distribution Partnership

Lingo Media to Present at the 2016 Microcap Conference Toronto on April 12th

Telefonica and Lingo Media Enter Into a Distribution Partnership for Peru

Immune Therapeutics, Inc. (IMUN)

The QualityStocks Daily Newsletter would like to spotlight Immune Therapeutics, Inc. (IMUN). Today, Immune Therapeutics, Inc. closed trading at $0.165, up 10.07%, on 684,995 volume with 74 trades. The stock’s average daily volume over the past 60 days is 207,405, and its 52-week low/high is $0.045/$0.36.

Immune Therapeutics, Inc. announced today it is providing shareholders with a status update of Immune Therapeutics, Inc.'s (IMUN) drug development program in China with long-term partner Hubei Qianjiang Pharmaceutical Co. Ltd (Qianjiang). The Economist Intelligence Unit (EIU) projects $166 billion in drug sales in China by 2017, providing a recognized market to further growth. China, potentially one of the largest pharmaceutical markets in the world, is not yet mature. The combined forces of economic and demographic development, government stimulus, enhanced health awareness among the public, market consolidation, and improved R&D capabilities will help the country to mature into a sophisticated market within the next decade.

Immune Therapeutics, Inc. (IMUN) is a biotechnology company applying its patented immunotherapy to combat chronic, life-threatening diseases that affect persons around the world. Building on the power of the body's natural immune system, the company's pipeline of products and immunotherapy technologies are designed to enhance treatment of cancer, infections such as HIV/AIDS, chronic inflammatory diseases, and a variety of autoimmune diseases.

Immune Therapeutics' most advanced clinical programs involve immunotherapy with met-enkephalin (MENK) (sometimes referred to as opioid growth factor) and its low dose naltrexone product (LDN), internationally known as Lodonal™, both of which have been shown to stimulate immune systems even in patients with advanced cancer.

Additionally, Immune Therapeutics is pursuing additional investigations for MENK and LDN as viable treatments for autoimmune conditions such as rheumatoid arthritis and multiple sclerosis; as an adjunct in cancer patients undergoing chemotherapy, radiation treatments or surgery; and as a complement to antibiotics in the treatment of a variety of infectious diseases, including patients with HIV/AIDS, in combination with retroviral drug therapy.

Immune Therapeutics and partners AHAR Pharma and GB Pharma Holdings recently completed a bridging trial to determine the safety and efficacy of LDN in patients with HIV, and have submitted data in connection with the filing of its New Drug Application for LDN with The National Agency for Food and Drug Administration and Control, (NAFDAC) of Nigeria. Disclaimer

Immune Therapeutics, Inc. Company Blog

Immune Therapeutics, Inc. News:

Immune Therapeutics, Inc. Provides Drug Development Program Status Update on Methionine-Enkelphine ("MENK") in China

Immune Therapeutics, Inc. (IMUN) Using the Power of the Body to Fight Cancer and AIDS

Immune Therapeutics, Inc., Appoints Two New Board Members

GTX Corp. (GTXO)

The QualityStocks Daily Newsletter would like to spotlight GTX Corp. (GTXO). Today, GTX Corp. closed trading at $0.0141, up 4.44%, on 302,400 volume with 12 trades. The stock’s average daily volume over the past 60 days is 306,058, and its 52-week low/high is $0.005/$0.02.

GTX Corp. announced today that it has entered into a mutual referral agreement with COPsync, Inc. (NASDAQ: COYN), a technology company that improves law enforcement communication in a manner that saves officers' lives and helps them prevent and respond more quickly to crime. Under the terms of the agreement, the two companies will provide joint referral and introduction services, initially targeting law enforcement agencies, care facilities, and hospitals.

GTX Corp. (GTXO), through its robust IoT enterprise monitoring platform and licensing, subscription recurring revenue business model, offers a complete end-to-end solution backed by an extensive portfolio of patents with filing dates going back as early as 2002, patents pending, registered trademarks, copy rights and URLs. GTX was featured in a 38-page research piece outlining the value proposition of the company's IP portfolio, and was also published in a SeeThruEquity research report discussing the value of the company's IP.

GTX has established a growing global distribution network with partners in more than 20 countries, and has garnered millions of dollars' worth of free media with coverage on CNN, Good Morning America, The Doctors, Fox News, Discovery Channel, ABC, NBC, CBS, The New York Times, LA Times, U.S.A. Today, the LA Business Journal, AARP and hundreds of other television, radio, magazine and newspaper media outlets across the globe.

The company's flagship, patented GPS SmartSoles were recently showcased in Munich at the Telefonica Digital Innovation Day 2015; was featured in AARP's 2015 technology gear guide; and came in second place, with Microsoft finishing first and Samsung taking third, in the 2015 Wearables, Health, Fitness & Wellness category at CTIA's Hot for the Holidays Awards competition.

As GTX continues to expand its brand awareness and distribution channels both domestically and internationally, in parallel it also plans to introduce new products with an emphasis on e-health and wellness. Corporate strategies are guided by a visionary management team with the insight and experience needed to navigate the plentiful opportunities and potential market share in the emerging multibillion IoT and Wearable Tech industries.

"With approximately 2% of the population having been diagnosed with Alzheimer's, dementia, autism, TBI or some other cognitive disorder which may lead to wandering due to memory loss, GTX plays a vital role in the safety, security and recovery of these individuals and their caregivers." --- Patrick Bertagna GTX Corp CEO. Disclaimer

GTX Corp. Company Blog

GTX Corp. News:

COPsync and GTX Corp Sign Mutual Referral Agreement for Products Targeting Law Enforcement and Safety

SeeThruEquity Issues Update on GTX Corp. (OTC: GTXO) Highlighting Patent Portfolio and Expanding Distribution

GTX Corp. (GTXO) Interviewed Alongside Industry Giants like Cisco and FBI Veteran Steve Cocco on Security Threats and Solutions by SecuritySolutionsWatch.com

Laguna Blends Inc. (LAGBF)

The QualityStocks Daily Newsletter would like to spotlight Laguna Blends Inc. (LAGBF). Today, Laguna Blends Inc. closed trading at $0.123, even for the day. The stock’s average daily volume over the past 60 days is 1,615, and its 52-week low/high is $0.10/$0.192.

Laguna Blends Inc. is pleased to announce it has started beta testing Laguna World with independent affiliates. Laguna will be gathering affiliate input to ensure Laguna provides the best possible marketing and communication tools. Laguna World is now live and available for all Laguna affiliates. Laguna is the first network marketing company to use exciting virtual, 3D technology to enable affiliates to train, recruit and drive sales by utilizing a simple interactive, voice conferencing platform. Laguna will offer opportunity meetings, training and customer support in Laguna World.

Laguna Blends Inc. (LAGBF) is a network marketing company focused on the generation of sales through independent affiliates. Leveraging innovative tools and technologies, the company's affiliates are able to build international businesses from their own homes while effectively capitalizing on the performance of some of the world's most rapidly expanding, in-demand markets. To date, Laguna's primary focus has been on the hyper growing hemp food and beverage marketplace. As part of these efforts, the company introduced Caffe, a hemp-infused instant coffee product, and is preparing to launch Pro369, a water soluble hemp protein powder.

As a network marketing company, Laguna is strategically positioned to grow very quickly following its entry into the rapidly expanding hemp market space. In early March 2016, the company gave prospective shareholders a preview of this potential when it launched sales of its protein coffee beverage through 135 independent affiliates throughout the United States and Canada. In less than a week, Laguna's affiliate base grew by more than 100 percent to include 278 independent marketers, demonstrating the high levels of demand for functional beverage products across North America, as well as the considerable interest in the viable business opportunity Laguna presents to its affiliates.

Through the commercialization of Caffe and Pro369, Laguna is establishing a foothold in two high-demand global markets. According to reports from the Coffee Association of Canada (CAC), coffee is consumed by a larger proportion of adults than any other beverage, excluding water. In recent years, the emergence of energy drinks has slowed the coffee industry's performance, but the single cup serving market, of which Caffe is a part, has maintained steady growth, rising above 32 percent market share as of January 2014, according to Mintel Research. With a product in this space - as well as the global hemp industry, which was valued at nearly $500 million in 2012 by the Hemp Industries Association - Laguna's initial offerings position it strongly for sustainable growth.

With growth through its marketing network already underway, Laguna has turned its attention toward further expansion of its product line. In March 2016, the company signed a letter of intent with Robert Lamberton Consulting regarding the development of a "Limitless functional beverage brain health and memory coffee" product. Under the terms of this LOI, all hard costs associated with the development of the product will be billed to Robert Lamberton Consulting. The two parties are expected to enter into a formal research and development agreement outlining the details of this arrangement in the second quarter of 2016.

Laguna is the first network marketing Company to use exciting virtual 3D technology to enable affiliates to train, recruit and drive sales by utilizing a simple interactive platform. Laguna believes this technology is a game changer in the Direct Selling / Network Marketing Industry. Disclaimer

Laguna Blends Inc. Company Blog

Laguna Blends Inc. News:

Laguna Initiates Phase One of LagunaWorld.com Virtual 3D Community and Introduces Charles Carleton as Head Technical Advisor of Laguna World

Laguna Introduces Pro369 Hemp Protein Beverage and Expands to Over 700 Independent Affiliates

Laguna Blends is Helping Improve Your Everyday Lifestyle, CEO Clip Video

Giggles N' Hugs, Inc. (GIGL)

The QualityStocks Daily Newsletter would like to spotlight Giggles N' Hugs, Inc. (GIGL). Today, Giggles N' Hugs, Inc. closed trading at $0.095, up 90.00%, on 1,500 volume with 1 trade. The stock’s average daily volume over the past 60 days is 34,213, and its 52-week low/high is $0.0137/$0.2799.

Los Angeles-based Giggles N' Hugs, Inc. (GIGL) is a first-of-its-kind, award-winning family restaurant and play space that combines organic gourmet food with the play elements for children in a 2500-square-foot play space in the middle of the restaurant. The concept is similar to Chuck E. Cheese, but offers a unique healthier, high-end version for health conscious parents and families. Parents eat and relax while the kids have an incredible time playing in the custom-made play area with giant climbers, dragons, castles, pirate ships slides and swings and a multitude of other toys.

In addition to nightly shows and concerts, every 30 minutes Giggles N' Hugs provides an activity such as face painting, disco dance parties, karaoke, games, arts and crafts, and much more. Giggles N' Hugs has been voted the No. 1 family restaurant, No. 1 birthday party place, and the No. 1 indoor play space in all of Los Angeles, and has attracted a star-studded list of customers including Sandra Bullock, Heidi Klum, Jessica Alba, Halle Berry, Jennifer Garner and Ben Affleck, Denis Quaid, Mark Whalberg, Adam Sandler, Dustin Hoffman and many more.

Revenue is derived from several sources, including food and beverage sales, beer and wine, birthday parties (40%), admission and membership fees to play, along with retail sales. These revenue-generating locations are also highly sought-after tenants. The company currently has three locations in the top premier malls around Los Angeles; four of the largest mall owners in the country are giving Giggles N' Hugs up to 75% discounts on rent and providing upward of $700,000 of upfront cash for each location to get Giggles N' Hugs into their malls around the country.

Growth and recognition of this caliber are driven by a very powerful management team. Giggles N' Hugs President John Kaufman was the COO at California Pizza Kitchen when the founders had just two locations. Joined by Giggles N' Hugs' CFO Phillip Gay, who at the time was CFO of California Kitchen, Kaufman grew the company from two to more than 100 locations – at which time it was bought by Pepsi Co. Kaufman was recruited as president of Koo Koo Roo Chicken, one of the fastest growing fast-casual concepts on the west coast, while Gay joined Wolfgang Puck Restaurants group as CFO, eventually becoming the CEO.

Giggles N' Hugs was founded as a truly "kid friendly" establishment catered specifically to the size, interests, and nutrition needs of children. Since opening its first Giggles N' Hugs in 2009, the company has received a steady stream of interest from more than 300 interested parties looking to expand the concept – via franchise or master licenses – in the U.S. as well globally in countries such as Germany, England, Dubai, Russia, Colombia, Australia , Singapore, Turkey, among the many more. Disclaimer

Giggles N' Hugs, Inc. Company Blog

Giggles N' Hugs, Inc. News:

Giggles N' Hugs, Inc. (GIGL) CEO Discusses 2016 Growth Strategies in Second QualityStocks Interview

Giggles Ní Hugs Signs Agreement with New York-Based Chardan Capital Markets

Giggles N Hugs to present at the 8th annual LD Micro Conference main event

graphic

Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters

graphic

1.

QualityStocks
(GIGL)

2.

Marketbeat.com
(PTSC)

3.

DSR News
(EGLE)

graphic
By The Numbers Charts
QualitystockTwits

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors
















 

The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.

 

About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251